A study of 48 people with signs of moderate alcohol-use disorder found that those taking low doses of semaglutide, currently produced by Novo ...
TD Cowen raised the firm’s price target on Axsome Therapeutics (AXSM) to $190 from $155 and keeps a Buy rating on the shares. The company ...
It's easy to miss this feature, but here's where to find it.
The Behring unit, which makes up around 70% of CSL's revenue, recorded a 15% jump in immunoglobulin sales to $3.17 billion, ...
The gas station owner, franchisee, or corporation wants to make money, so after they've paid their bills, they set their ...
Providers are sympathetic to Medicare enrollees’ concerns but don’t agree on their role in helping patients find less costly ...
West Australian Ballet's The Wild Between Stars comprises three different performances to showcase different choreographic styles and ambience.
Drugmakers offer “copay assistance programs” to help people afford expensive medicines. But health insurers are milking these ...
The company forecast 2025 revenue of around $45.5 billion, down from $48.3 billion in 2024 and below analyst expectations of $47.4 billion, according to LSEG data. It forecast 2025 earnings in the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback